In the BioHarmony Drug Report Database

"Preview" Icon

Dexmedetomidine

Dexmedetomidine, Precedex, Dexdor (dexmedetomidine) is a small molecule pharmaceutical. Dexmedetomidine was first approved as Dexmedetomidine on 1999-12-17. It is used to treat pain and psychomotor agitation in the USA. It has been approved in Europe to treat conscious sedation and premedication. It is known to target alpha-2B adrenergic receptor, alpha-2C adrenergic receptor, and alpha-2A adrenergic receptor. Precedex’s patents are valid until 2036-04-20 (FDA).

 

Trade Name

 

Dexdor
 

Common Name

 

dexmedetomidine
 

ChEMBL ID

 

CHEMBL778
 

Indication

 

conscious sedation, pain, premedication, psychomotor agitation
 

Drug Class

 

Image (chem structure or protein)

Dexmedetomidine structure rendering